



Sheep Anti-Human Factor VIII:C Peroxidase Conjugated IgG 0.2 mg

Cat No: SAF8C-HRP
Lot No: SAMPLE
Expiry date: **/****
Store at -10 to -20°C.

For Research Use Only.
~ Not for use in diagnostic procedures.

Description of Factor VIII (F.VIII)

Factor VIII (formerly referred to as antihemophilic globulin and Factor VIII:C) is a large glycoprotein (320 kDa) that circulates in plasma at approximately 200 ng/ml. Synthesized in the liver, the majority of Factor VIII is cleaved during expression, resulting in a heterogeneous mixture of partially cleaved forms of F.VIII ranging in size from 200-280 kDa. The F.VIII is stabilized by association with von Willebrand Factor to form a F.VIII-vWF complex required for the normal survival of F.VIII *in vivo* (t_{1/2} of 8-12 hours).

F.VIII is a pro-cofactor that is activated through limited proteolysis by thrombin. In this process F.VIIIa dissociates from vWF to combine with activated Factor IX, calcium and a phospholipid surface where it is an essential cofactor in the assembly of the Factor X activator complex. Once dissociated from vWF, F.VIIIa is susceptible to inactivation by activated Protein C and by non-enzymatic decay.

Hemophilia A is a congenital bleeding disorder resulting from an X-chromosome-linked deficiency of F.VIII. The severity of the deficiency generally correlates with the severity of the disease. Some Hemophiliacs (~10%) produce a F.VIII protein that is partially or totally inactive. The production of neutralizing antibodies to F.VIII also occurs in 5-20% of Hemophiliacs¹⁻³.

References and Reviews

1. Lollar P, Fay PJ, Fass DN: Factor VIII and Factor VIIIa. *Methods in Enzymology*, 222, pg 122, 1993.
2. Hoyer, LW, Wyshock EG, Colman RW, in *Hemostasis and Thrombosis*, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 109-133, J.B. Lippincott Co., Philadelphia, 1994.
3. Pittman DD, Kaufman RJ. Structure-Function Relationships of Factor VIII Elucidated through Recombinant DNA Technology. *Thromb. Haemostas*. 61:161-165, 1989.

Product Specifications

Description:

Vial containing 0.100 ml of whole IgG conjugated to horseradish peroxidase (HRP) through carbohydrate groups.
Total protein is 0.2 mg.

Format:

IgG-HRP conjugate as a clear, slightly red-brown liquid.

Host Animal:

Sheep

Immunogen:

Human F.VIII (F.VIII:C) purified from concentrate.

Concentration:

IgG-HRP concentration is 2.00 mg/ml, determined by absorbance using an extinction coefficient ($E_{280}^{1\%}$) of 14.

Buffer:

A buffered stabilizer solution containing 50% (v/v) glycerol.

Storage:

Store between -10 and -20 °C. Product will become viscous but will not freeze. Avoid storage in frost-free freezers. Keep vial tightly capped. Allow product to warm to room temperature and gently mix before use. Avoid exposure to sodium azide as this is an inhibitor of peroxidase activity.

Specificity:

Prior to conjugation, this antibody was specific for F.VIII as demonstrated by immunoelectrophoresis and ELISA.

Applications:

Suitable as a source of peroxidase-labeled antibodies to F.VIII.

Related Products

SAF8C-IG	Sheep Anti-Human FVIII, whole IgG from serum
SAF8C-AP	Sheep Anti-Human Factor VIII, affinity-purified IgG
F8C-EIA	Paired antibodies for FVIII ELISA, 4 x 96 wells
FVIII-DP	Human plasma deficient in F. VIII, immune depleted

Visit our site (www.enzymeresearch.co.uk).

Enzyme Research Laboratories Ltd
Glamorgan House . Charter Court . Enterprise Park .
Swansea. SA7 9DD. UK.
Tel: +44 (0)1792 686070
Email: info@enzymeresearch.co.uk
Website: www.enzymeresearch.co.uk